A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.
Hum Vaccin Immunother
; 10(6): 1499-504, 2014.
Article
en En
| MEDLINE
| ID: mdl-24632556
ABSTRACT
Campylobacter jejuni is a major cause of diarrheal disease and results in high levels of morbidity and economic loss in both industrialized and developing regions of the world. To date, prior vaccine approaches have failed to confer protection against this enteric pathogen. Key challenges to the development of a practical Campylobacter vaccine for human use include a lack of understanding of Campylobacter pathogenesis and well-defined immune correlates of protection. With the discovery that C. jejuni expresses a capsule polysaccharide associated with virulence, a conjugate vaccine approach is currently being evaluated. Conjugate vaccines have been successfully developed and implemented against other invasive mucosal pathogens including Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae. Furthermore, Shigella-based conjugate vaccines based on lipopolysaccharide have shown promising results in field trials. A prototype C. jejuni conjugate vaccine is currently entering human testing.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Infecciones por Campylobacter
/
Vacunas Bacterianas
/
Campylobacter jejuni
/
Cápsulas Bacterianas
/
Diarrea
Límite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2014
Tipo del documento:
Article